DelveInsight’s “Infectious Disease Diagnostics Market Insights, Epidemiology, and Market Forecast–2034” report offers an in-depth understanding of the Infectious Disease Diagnostics market, historical and forecasted trends, as well as the market dynamics in North America, Europe, Asia-Pacific, and the Rest of the World.

The latest healthcare forecast report provides an in-depth analysis of the Infectious Disease Diagnostics market, offering comprehensive insights into revenue trends, prevalence, and competitive landscape. The report delves into key market statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging diagnostic technologies. Additionally, the report covers ongoing clinical and product development activities, providing an overview of innovations poised to shape the future of infectious disease diagnostics.

To Know in detail about the Infectious Disease Diagnostics market outlook, technology uptake, and competitive landscape, Click here; Infectious Disease Diagnostics Market Forecast

Some of the Key Facts of the Infectious Disease Diagnostics Market Report:

• The Global Infectious Disease Diagnostics Market is expected to increase from USD 28,338.85 million in 2025 to USD 38,155.00 million by 2034, reflecting strong and sustained growth at a CAGR of 3.41% during the forecast period 2026–2034.
•  In January 2025, OraSure Technologies announced that the FDA approved a labeling change to the OraQuick® HIV Self-Test, increasing access to HIV testing for adolescents.
• In December 2024, R-Biopharm launched a new generation of tuberculosis diagnostics based on detection of the biomarker IP-10, secreted in concentrations up to 100 times higher than INF-gamma after specific T-cell stimulation with tuberculosis antigens.
•  In April 2024, Labcorp announced that the FDA granted Emergency Use Authorization (EUA) for its Mpox PCR Test Home Collection Kit to aid in the diagnosis of infection with non-variola Orthopoxvirus.
•  In December 2023, QuidelOrtho Corporation received 510(k) clearance from the U.S. FDA for its Savanna PCR platform and Savanna HSV 1+2/VZV test, enabling detection and differentiation of HSV-1, HSV-2, and VZV from lesion swabs.
• In October 2023, Molecular Designs announced the release of its new Direct-PCR Covid/Flu/RSV Simplicity Panel™, a multiplex RT-PCR assay for qualitative detection of respiratory viral nucleic acids.
• In February 2023, Thermo Fisher introduced Applied Biosystems TaqPath real-time PCR kits in India for the detection of MDR-TB, Hepatitis B, Hepatitis C, and HIV.
• North America is expected to account for the highest proportion of 41% of the Infectious Disease Diagnostics Market in 2025, driven by high prevalence of infectious diseases and advanced healthcare infrastructure.
• Asia-Pacific is identified as the fastest-growing regional market, driven by rising disease burden, expanding healthcare infrastructure, and increasing adoption of molecular diagnostics.
• In the type segment, Reagents & Kits under the products category contribute to approximately 65% of the total market revenue in 2025.
•  Within the technology segment, Polymerase Chain Reaction (PCR) under the molecular diagnostics category dominates, accounting for around 55% of the market share in 2025.
•  Within the test type segment, laboratory-based tests account for approximately 75% of the market share in 2025.
•  Within the application segment, the viral disease category dominates with approximately 47% of the market share in 2025.
•  According to the WHO, in 2024, an estimated 10.7 million people fell ill with tuberculosis worldwide, and approximately 1.3 million people acquired HIV globally.

Key Infectious Disease Diagnostics Companies: 

Hoffmann-La Roche Ltd., Abbott Laboratories, Bio-Rad Laboratories, Inc., Danaher Corporation, Thermo Fisher Scientific Inc., QIAGEN, bioMérieux, Siemens Healthineers AG, DiaSorin S.p.A., Hologic, Inc., Sysmex Corporation, QuidelOrtho Corporation, BD, OraSure Technologies, Inc., Seegene Inc., and others.

Key Infectious Disease Diagnostics Technologies: 

Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Nucleic Acid Amplification Tests (NAAT), Immunodiagnostics, Microbial Cultures, Point-of-Care Testing, CRISPR-Based Diagnostics, AI-Integrated Diagnostics, and others.

The Infectious Disease Diagnostics market is expected to surge due to the rising prevalence of infectious diseases and growing demand for accurate diagnostic solutions. Furthermore, continuous product development activities and technological advancements will significantly revolutionize the Infectious Disease Diagnostics market dynamics during the forecast period.

Infectious Disease Diagnostics Overview

The Infectious Disease Diagnostics market comprises diagnostic tests, assays, instruments, and services utilized for the detection and identification of causative agents responsible for infectious diseases. Rising prevalence of conditions such as tuberculosis, influenza, hepatitis, HIV/AIDS, COVID-19, dengue, malaria, and other emerging viral and bacterial infections is significantly increasing the global demand for rapid, reliable, and accurate diagnostic solutions. The growing burden of both chronic and acute infectious diseases has intensified the need for early diagnosis to prevent disease transmission, improve patient outcomes, and reduce healthcare costs. Frequent outbreaks of emerging and re-emerging pathogens, coupled with increasing global travel and urbanization, are further accelerating the requirement for efficient infectious disease surveillance and testing systems across hospitals, diagnostic laboratories, clinics, and home-care settings.

Get a Free sample for the Infectious Disease Diagnostics Market Forecast

Infectious Disease Diagnostics Market Segmentation

The market segmentation section provides insights into the historical, current, and forecasted trends across key segments in the global Infectious Disease Diagnostics market from 2023 to 2034. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders, providing a detailed analysis of market dynamics across product types, technologies, applications, and geographies.

Infectious Disease Diagnostics Market Segmentation:

The Infectious Disease Diagnostics market report proffers detailed analysis for the study period 2026–2034 segmented into:

• By Type: Products (Instruments and Reagents & Kits) and Services
• By Technology: Molecular Diagnostics (PCR, NGS, NAAT, and Others), Immunodiagnostics, Microbial Cultures, and Others
• By Test Type: Laboratory-Based Tests and Point-of-Care (POC) Tests
• By Application: Viral Diseases, Bacterial Diseases, and Others
• By End-Users: Hospitals, Diagnostic Labs, and Others
• By Geography: North America, Europe, Asia-Pacific, and Rest of the World

Download the report to understand which factors are driving Infectious Disease Diagnostics market trends @ Infectious Disease Diagnostics Market Forecast

Infectious Disease Diagnostics Products Uptake and Pipeline Development Activities

The products uptake section focuses on the rate of uptake of advanced diagnostic technologies and newly launched products in the Infectious Disease Diagnostics market or expected to be launched during the study period. The analysis covers market uptake by technology, end-user adoption by testing platforms, and revenue contribution of each product segment.

Moreover, the competitive assessment section helps understand the diagnostic technologies and platforms with the most rapid adoption and the reasons behind their widespread use. Additionally, it compares companies and products based on market share.

The report also covers the Infectious Disease Diagnostics pipeline development activities. It provides valuable insights about different emerging technologies in various stages of development and the key companies involved. It also analyzes recent developments such as collaborations, acquisitions, mergers, regulatory approvals, and other information for emerging diagnostic platforms.

Discover more about technologies set to grab major Infectious Disease Diagnostics market share @ Infectious Disease Diagnostics Competitive Landscape

Infectious Disease Diagnostics Market Strengths

• Continuous innovation in molecular diagnostic technologies—including PCR, NGS, multiplex assays, CRISPR-based detection, and AI-integrated platforms—is expanding diagnostic accuracy, speed, and accessibility across global healthcare settings.
• The growing adoption of point-of-care and home-based testing solutions, such as Abbott’s BinaxNOW and OraQuick’s HIV Self-Test, is decentralizing diagnostics and increasing testing volumes outside traditional laboratory settings.
• Strong regulatory support, including multiple FDA approvals, Emergency Use Authorizations, and CE markings, is accelerating the launch and adoption of advanced infectious disease diagnostic products.

Infectious Disease Diagnostics Market Opportunities

• Rapid urbanization, increasing global travel, and the persistent risk of novel pathogen outbreaks are creating sustained demand for scalable, high-throughput, and portable infectious disease diagnostic solutions worldwide.
• The integration of AI-driven analytics, digital health platforms, and portable diagnostic devices is enhancing testing accessibility in remote and resource-limited settings, opening significant growth opportunities in emerging economies across Asia-Pacific, Latin America, and Africa.

Scope of the Infectious Disease Diagnostics Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Companies: Incyte, Agios Pharmaceuticals/Servier Pharmaceuticals, Taiho, TransThera Sciences, Senhwa Biosciences, Lisata Therapeutics, Relay Therapeutics, Genoscience Pharma, Virogin Biotech, and others
• Key Therapies: PEMAZYRE (pemigatinib), TIBSOVO (ivosidenib), LYTGOBI (futibatinib), Tinengotinib, Silmitasertib (CX-4945), LSTA1, RLY-4008, GNS561 + trametinib, VG161, and others
• Therapeutic Assessment: Cholangiocarcinoma current marketed and emerging therapies
• Market Dynamics: Cholangiocarcinoma market drivers and Cholangiocarcinoma market barriers
• Competitive Intelligence: SWOT analysis, PESTLE analysis, Porter’s Five Forces, BCG Matrix, and market entry strategies

To know more about Infectious Disease Diagnostics companies working in the market, visit @ Infectious Disease Diagnostics Competitive Assessment

Table of Contents

1. Infectious Disease Diagnostics Market Report Introduction

2. Executive Summary for Infectious Disease Diagnostics

3. SWOT Analysis of Infectious Disease Diagnostics

4. Infectious Disease Diagnostics Market Overview at a Glance

5. Infectious Disease Diagnostics Disease Background and Overview

6. Infectious Disease Diagnostics Market Segmentation and Analysis

7. Regional Analysis of the Infectious Disease Diagnostics Market

8. Country-Specific Infectious Disease Diagnostics Market Analysis

9. Competitive Landscape and Key Company Profiles

10. Infectious Disease Diagnostics Unmet Needs

11. Infectious Disease Diagnostics Emerging Technologies and Pipeline

12. Infectious Disease Diagnostics Market Outlook

13. Infectious Disease Diagnostics Market Access and Reimbursement

14. Infectious Disease Diagnostics Market Drivers

15. Infectious Disease Diagnostics Market Barriers

16. Infectious Disease Diagnostics Recent Developments

17. Infectious Disease Diagnostics Appendix

18. Infectious Disease Diagnostics Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma and diagnostics companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Mehul Malhotra

Email: info@delveinsight.com

Phone: +14699457679

Address: 304 S. Jones Blvd #2432, Las Vegas, Nevada 89107, United States

Website: https://www.delveinsight.com/